On Jan. 15, HHS said it would update its guidelines to exempt physicians from the X waiver, a requirement mandated by Congress in 2000 that necessitates physicians receive a day’s training before they can prescribe buprenorphine, a drug that treats opioid addiction and chronic pain. Before he was elected, President Biden’s plan to end the opioid crisis supported this measure.
However, since President Biden took office, legal experts have warned the White House administration that HHS is not authorized to issue guidelines that allow physicians to eschew requirements Congress mandated, sources told the newspaper.
“Unfortunately, the Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder announced by the Trump administration in its last days had significant legal and clinical concerns,” a draft announcement obtained by the Washington Post reads. “The Biden administration will not issue the guidelines previously announced.”
More articles on pharmacy:
Merck abandons its 2 COVID-19 vaccine candidates
CivicaRx to build drug manufacturing facility in Virginia
CVS says it’s completed first-round COVID-19 shots for skilled nursing facilities
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
